Format

Send to

Choose Destination
Pediatr Nephrol. 2010 Oct;25(10):2021-34. doi: 10.1007/s00467-010-1498-x. Epub 2010 Mar 30.

When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes.

Author information

1
Division of Nephrology, MS#40, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA. klemley@chla.usc.edu

Abstract

Angiotensin converting enzyme inhibitors (ACEI) and angiotensin 2 receptor blockers (ARB) have become a mainstay of adjunctive therapy for the prevention and amelioration of diabetic nephropathy. Although ACEI were shown over 20 years ago to slow the rate of loss of renal function in diabetic subjects with decreased renal function, the question of how early in the course of diabetes to introduce them remains unresolved. Recent studies suggest that very early initiation of ACEI/ARB therapy may not have demonstrable beneficial effects even over a period of years.

PMID:
20352458
DOI:
10.1007/s00467-010-1498-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center